Arbutus Biopharma (ABUS) Capital Expenditures (QoQ) (2013 - 2024)
Arbutus Biopharma (ABUS) Capital Expenditures (QoQ) (2013 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -98.95% |
| Sep 30, 2023 | -96.27% |
| Jun 30, 2023 | 634.19% |
| Mar 31, 2023 | -12.69% |
| Dec 31, 2022 | 47.25% |
| Sep 30, 2022 | -57.08% |
| Jun 30, 2022 | 182.67% |
| Mar 31, 2022 | 29.31% |
| Dec 31, 2021 | 190.00% |
| Sep 30, 2021 | -96.84% |
| Jun 30, 2021 | 538.38% |
| Mar 31, 2021 | -34.87% |
| Dec 31, 2020 | 1,281.82% |
| Sep 30, 2020 | -83.33% |
| Dec 31, 2019 | -75.29% |
| Sep 30, 2019 | 6.25% |
| Jun 30, 2019 | 674.19% |
| Mar 31, 2019 | -86.34% |
| Dec 31, 2018 | -4.22% |
| Sep 30, 2018 | -44.24% |